Please assess the completion status of the following clinical trial:

Trial Title: Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven squamous, adenosquamous or adenocarcinoma International Federation of Gynecology and Obstetrics (FIGO) Stage IB-IVA of the uterine cervix undergoing initial radiation and cisplatin based chemotherapy for primary treatment.~* Gynecologic Oncology Group performance status of 0, 1, or 2.~* Patients with ureteral obstruction must undergo stent placement or nephrostomy tube placement prior to study entry.~* Age \>= 18 years.~* Patients must have signed informed consent.~* Patients must have adequate:~  * Bone marrow function: absolute neutrophil count (ANC) greater than or equal to 1,500/ul, equivalent to Common Toxicity Criteria (CTCAE) grade 1. Platelets greater than or equal to 100,000/ul.~ * Renal function: creatinine less than or equal to 1.5 x institutional upper limit normal (ULN). If creatinine is greater than 1.5 x ULN, creatinine clearance must be greater than 60 ml/min.~ * Hepatic function: bilirubin less than or equal to 1.5 x ULN. AST and alkaline phosphatase less than or equal to 2.5 x ULN.~ * Neurologic function: neuropathy (sensory and motor) less than or equal to CTCAE grade 1.~ * Coagulation: prothrombin time (PT) such that the international normalized ratio (INR) is \< 1.5 (INR may be between 2 and 3 if a patient is on stable dose of therapeutic warfarin) and a PTT \< 1.2 times control.~Exclusion Criteria:~* Evidence of sepsis or severe infection.~* Previous or current treatment for osteoporosis. Patients with denovo osteoporosis are also excluded.~* Evidence of bone metastasis.~* Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), or exposed bone in the mouth, or of slow healing after dental procedures.~* Recent (within 6 weeks) or planned dental or jaw surgery (e.g., extraction, implants).~* Patients with history of other invasive malignancy (treatment within the last 5 years) other than non-melanoma skin cancer.~* Patients with known hypersensitivity to Zometa or other bisphosphonates.~* Patients who are pregnant or breast feeding.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (No Zometa) (Type: NO_INTERVENTION): Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. All interventions on this arm are standard of care.
- Arm 2 (Zometa) (Type: EXPERIMENTAL): Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. Women randomized to zoledronic acid will receive 4 mg intravenously (IV) with their first dose chemotherapy and 3, 6 and 9 months after completion of radiation (total of 4 doses) along with scheduled follow-up dual-energy X-ray absorptiometry (DEXA) and biomarker studies.

Based on this trial design, predict the completion outcome and termination type (if applicable).